Analyst Reco. FibroGen, Inc.

Equities

FGEN

US31572Q8087

Real-time Estimate Cboe BZX Other stock markets 15:04:39 30/04/2024 BST			5-day change	1st Jan Change
1.09 ^USD	0.00%		+1.87%	+22.98%

04-24	FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting	CI
04-15	Faron Pharmaceuticals reappoints former finance chief on interim basis	AN

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Analyst recommendations: Hewlett Packard, Apple, Tesla, Mosaic, Rite Aid...	30/08/23
BofA Downgrades FibroGen to Underperform From Neutral, Adjusts Price Target to $2 From $4	08/08/23	MT
BofA Securities Downgrades FibroGen to Neutral From Buy, Lowers Price Target to $4 From $29 After Drug Fails to Meet Phase 3 Trial Goal	27/06/23	MT
BofA Securities Downgrades FibroGen to Neutral From Buy, Lowers Price Target to $4 From $29	27/06/23	MT
Goldman Sachs Adjusts FibroGen's Price Target to $2 From $16, Keeps Sell Rating	27/06/23	MT
Stifel Downgrades FibroGen to Hold From Buy, Cuts Price Target to $11 From $28	26/06/23	MT
William Blair Downgrades FibroGen to Market Perform From Outperform	26/06/23	MT
Raymond James Downgrades FibroGen to Market Perform From Outperform	26/06/23	MT
Stifel Upgrades FibroGen to Buy From Hold	02/06/23	MT
Cowen Adjusts Price Target on FibroGen to $25 From $15, Maintains Market Perform Rating	28/02/23	MT
Goldman Sachs Increases Price Target on FibroGen to $16 From $9, Maintains Sell Rating	21/02/23	MT
William Blair Upgrades FibroGen to Outperform From Market Perform	31/01/23	MT
Raymond James Upgrades FibroGen to Outperform From Market Perform, Price Target is $35	26/01/23	MT
BofA Securities Upgrades FibroGen to Buy From Neutral, Adjusts Price Target to $27 From $18	05/01/23	MT
Goldman Sachs Adjusts Price Target on FibroGen to $9 From $8, Maintains Sell Rating	08/11/22	MT
Goldman Sachs Adjusts FibroGen's Price Target to $8 from $9, Keeps Sell Rating	24/05/22	MT
Goldman Sachs Trims Price Target for FibroGen to $9 From $10, Maintains Sell Rating	01/03/22	MT
FIBROGEN : Goldman Sachs Downgrades FibroGen to Sell Rating From Neutral, Adjusts Price Target to $11 From $16	22/09/21	MT
FIBROGEN : Raymond James Upgrades FibroGen to Market Perform From Underperform	20/08/21	MT
FIBROGEN : Goldman Sachs Further Cuts FibroGen's Price Target to $16 From $22, Maintains Neutral Rating	12/08/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. FibroGen, Inc.

Equities

FGEN

US31572Q8087

Analyst Reco.

Filters